GlassScriptPhysician profile
Andrew P Royer
NPI 1255435657
$23,464.95
in general payments reported to CMS, 2019-2025
26 companies · $7,813 in 2025
The $7,813 reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $722 · 2020: $650 · 2021: $1,346 · 2022: $2,824 · 2023: $2,804 · 2024: $7,306 · 2025: $7,813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,388 · Food and Beverage: $8,382 · Education: $99.99 · Honoraria: $53.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,387.50 |
| Food and Beverage | $8,382.28 |
| Education | $99.99 |
| Honoraria | $53.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $5,479.66 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Dompe US, INC. | $3,100.95 | 2019-2025 | Oxervate |
| Abbvie INC. | $2,405.21 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Tarsus Pharmaceuticals, INC. | $1,588.83 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $1,384.46 | 2019-2025 | Cequa, Xelpros |
| Oyster Point Pharma, INC. | $1,372.56 | 2022-2025 | Tyrvaya |
| Biotissue Holdings INC. | $1,191.07 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,169.66 | 2019-2023 | |
| Alcon Vision LLC | $1,158.69 | 2019-2025 | Tryptyr, Rocklatan, Eysuvis |
| Allergan, INC. | $863.09 | 2019-2022 | |
| Glaukos Corporation | $628.18 | 2022-2025 | Istent Inject Trabecular Micro-Bypass System, Gsw-Istentinjectwtrabecular Micro-Bypass System, Istent Inject Trabecular Micro-Bypass System |
| Harrow Eye, LLC | $612.62 | 2024-2025 | Vevye |
| Kala Pharmaceuticals, INC. | $585.06 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $582.77 | 2023-2025 | Acthar |
| Rxsight INC | $347.51 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $208.35 | 2023 | Tepezza |
| Eyevance Pharmaceuticals LLC | $151.84 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $122.56 | 2020 | |
| Thea Pharma INC. | $92.18 | 2023-2025 | Iyuzeh |
| Ucb, INC. | $90.00 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $84.15 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $77.49 | 2025 | Purified Cortrophin Gel |
| Tearlab Corp | $73.02 | 2019-2023 | Tearlab Osmolarity System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $65.18 | 2019-2021 | |
| Ocular Therapeutix, INC. | $17.80 | 2023 | Dextenza |
| Aerie Pharmaceuticals, INC. | $12.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Royer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.